 Started: - with $200,000 and 3 scientists - in a small laboratory at Seoul National University - in November,  First university-based venture company in Korea  First gene medicine company in Korea

Seoul National University Graduate Students High quality Manpower Capital Technology Intellectual Property - Patents - Scientific papers MOST MOCIE  Governmental support was instrumental at the commencement stage.  However, the company needed a critical amount of money for growth.  Domestic company was too conservative to invest in long-term, high risk projects. Gove rnment

CEO: Sunyoung Kim, D. Phil. Established: Nov. 21, 1996 Listed on Korean KOSDAQ market (December, 2005) Total Personnel: 66 Market Cap: US $ million

Most Active Biotech Company in Korea - Phase II for 1 product (China) - Phase I for 1 product (US, Korea and China) - Phase I/II for 1 product (Korea) - Phase I planned for 1 anti-cancer product in 2009 (Korea) - Active R & D in progress for cancer and autoimmune diseases Target Markets US, Japan, EU, China, Korea, etc. Global Competitiveness - Out-licensing Records (UK, Japanese, and Chinese Companies) - Global Capital Placement - Patents Issued in Major Countries Including the US, Japan, EU, etc. - Scientific Papers Published in Renowned International Scientific Journals

Recombinant Protein DNA-Based Virus-Based Retrovirus Adenovirus Naked DNA VM202 (phase I) Critical Limb Ischemia Coronary Artery Disease VM206 (pre-clinical) Anti-Cancer Genetic Vaccine VM106 (phase I/II) Chronic Granulomatous Disease VM501 (phase II) Thrombocytopenia Clinical Trial R&D Rheumatoid Arthritis Cancer Psoriasis Multiple Sclerosis Genetic Diseases Cancer Phase II 1 Phase I/II 1 Phase I 3 Phase I 2 (Planned in 2009) Cancer (1) Autoimmune diseases(1)

p(HCMV) pA(BGH) ColE1 (Kan r ) e1 e2 HGF-X7 VM202 (Backbone: pCK) VM202 Angiogenic medicine for ischemic cardiovascular diseases Company’s proprietary expression system pCK Designed to produce the two isoforms of human HGF (723 and 728 amino acids) Effects: Formation of new blood vessels Patents: Issued in Japan, Europe, Korea, Singapore, China and Hong Kong and filed in the US and Brazil

Target: Coronary Artery Disease Direct Injection Catheter Drug-Eluting Stent World market size of gene medicine for cardiovascular diseases: > $3.3 B by year 2015 (Jain Pharmabiotech, 2006) No. 1 or 2 cause of death in all major countries

- Hospitalization of about 250,000 patients annually in the US - World market size in peripheral artery disease: $1.5B (DataMonitor, 2004) Target : Peripheral Artery Disease Day 1 (Pre-dose) Day 59 Day 15 Day 90 (Ischemic Limb Disease)

Coronary Artery Disease (Myocardial Infarction, Angina Pectoris) Peripheral Artery Disease Diabetic Neuropathy Direct injection on Heart muscle By CatheterDrug-Eluting Stent Direct Muscle Injection Phase I (Korea) Ongoing (6/9) Phase I (US) 2009 Pre-clinical Phase I (US) Enrollment completed (12/12) Phase I (China) Enrollment started (0/21) VM202 A leading cause of death in developed countries 911,000 deaths annually in the US Approximately 16 million patients in the US experience CAD Estimated 8 million Americans (symptoms of PAD) About 250,000 patients hospitalized annually in the US Phase I/II (US) Planned for DN

Cancer patient Genetically Modified IL-11 Original wild type IL-11 → Highly toxic VM501

CTL Antibody Her2 expressing cancer cells Her2 IND Submission in 1Q, Phase I trial planned in 3Q, Pre-clinical experiments have been completed in murine, canine, and primate models.

Recombinant Protein DNA-Based Virus-Based Retrovirus Adenovirus Naked DNA VM202 (phase I) Critical Limb Ischemia Coronary Artery Disease VM206 (pre-clinical) Anti-Cancer Genetic Vaccine VM106 (phase I/II) Chronic Granulomatous Disease VM501 (phase II) Thrombocytopenia Clinical Trial R&D Rheumatoid Arthritis Cancer Psoriasis Multiple Sclerosis Genetic Diseases Cancer Phase II 1 Phase I/II 1 Phase I 3 Phase I 2 (Planned in 2009) Cancer (1) Autoimmune diseases(1)

ViroMed is a multi-portfolio biopharmaceutical company with solid multiple technology platforms. ViroMed is a unique and sophisticated biotech company, poised to become a significant global player in the field. ViroMed has developed 4 products, that are under phase I or phase II human trials in the US, China, and Korea. In addition, 2 products are being actively developed for cancer and autoimmune diseases. ViroMed has grown from a small university-born company to one of the most active biopharmaceutical companies in Asia.